Invivyd, Inc. · NASDAQ:IVVD
Invivyd — Investor Presentation (June 2023)
18 slides from Invivyd's investor presentation, Jun 29, 2023
Slide 1: Corporate Overview June 2023
Exhibit 99.1 Corporate Overview June 2023 © 2023 Invivyd, Inc. Invivyd and the Invivyd logo are trademarks of Invivyd, Inc. All trademarks in this presentation are the property of their respective owners.
Slide 2: Cautionary Note Regarding Forward-Looking Statements
CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS This presentation contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Statements in this presentation that are not statements of historical fact are forward-looking statements. Words
Slide 3: Urgent need for new therapeutics that protect immunocompromised people from COVID-19
THERE IS AN URGENT NEED FOR NEW THERAPEUTICS THAT PROTECT IMMUNOCOMPROMISED PEOPLE FROM COVID-19 Now, many people who are not well- “ protected by vaccines are in a dangerous and isolating situation—especially because the arsenal of effective COVID-19 treatments is shrinking for everyone as the viru
Slide 4: Millions of immunocompromised people are in urgent need of new therapeutics
MILLIONS OF IMMUNOCOMPROMISED PEOPLE ARE IN URGENT NEED OF NEW THERAPEUTICS THAT PROVIDE PASSIVE IMMUNITY TO COVID-19 1-3 8-18M people in the U.S. 4 14M people in the E.U. Organ are estimated to be immunocompromised due to a transplant medical condition or immunosuppressive medication or recipients
Slide 5: Many immunocompromised people have an impaired response to vaccines
MANY IMMUNOCOMPROMISED PEOPLE HAVE AN IMPAIRED RESPONSE TO VACCINES AND HAVE LESS PROTECTION AGAINST SEVERE COVID-19 OUTCOMES Immunocompromised people are less likely to have detectable SARS- Immunocompromised people generate less protection against severe CoV-2 antibodies following vaccination than
Slide 6: Vaccine effectiveness has waned in the face of viral evolution
EVEN IN PRIMARILY IMMUNOCOMPETENT POPULATIONS, VACCINE EFFECTIVENESS (VE) HAS WANED IN THE FACE OF VIRAL EVOLUTION 4-29% VE against infection with more recent Omicron 45.7% VE against symptomatic Omicron B.1.1.529 at ≥10 wks after variants up to 26 weeks from mRNA bivalent booster two doses of the B
Slide 7: Prevention of COVID-19 in vulnerable populations is a long-term, potentially large opportunity
WE BELIEVE PREVENTION OF COVID-19 IN VULNERABLE POPULATIONS IS A LONG-TERM, POTENTIALLY LARGE OPPORTUNITY $2.2B in total revenue of Evusheld® in 2022, a mAb previously authorized to protect vulnerable populations from COVID-19 $1,400 $1,270M $1,200 $1,000 $914M $800 $600 $400 $135M $200 $0 H2 2021 H
Slide 8: Monoclonal antibodies play a critical role in the COVID-19 medicine cabinet
MONOCLONAL ANTIBODIES PLAY A CRITICIAL ROLE IN THE COVID-19 MEDICINE CABINET PREVENTION TREATMENT Vaccines mAbs Antivirals Anti-SARS-CoV-2 mAbs are expected to provide: Limitations for the • Rapid, passive immunity Limitations for the immunocompromised: immunocompromised: • Utility for prevention or
Slide 9: Invivyd is on a mission to rapidly and perpetually deliver monoclonal antibodies
INVIVYD IS ON A MISSION TO RAPIDLY AND PERPETUALLY DELIVER MONOCLONAL ANTIBODIES THAT HELP PROTECT THE VULNERABLE FROM COVID-19 Previous mAbs for the prevention of Combining expertise in virology, COVID-19 in vulnerable populations, such antibody engineering and predictive as immunocompromised peopl
Slide 10: Platform designed to rapidly deliver a stream of monoclonal antibodies
INVIVYD HAS A PLATFORM DESIGNED TO RAPIDLY DELIVER A STREAM OF MONOCLONAL ANTIBODIES TO KEEP PACE WITH VIRAL EVOLUTION Continuous monitoring of viral evolution coupled with rapid antibody discovery and engineering to address the evolving SARS-CoV-2 threat ~10 million B Cells MINE Mine human antibody
Slide 11: VYD222: engineered for broad activity and prolonged utility
VYD222: ENGINEERED FOR BROAD ACTIVITY AND PROLONGED UTILITY VYD222 is engineered from adintrevimab (ADG20), a product candidate that Invivyd took from IND to pivotal data in 16 months Designed for: • High potency VYD222 • Lack of polyreactivity • Long half-life • Developability • Potential to resist
Slide 12: Rapid advancement of VYD222 for prevention of symptomatic COVID-19
INVIVYD IS PURSUING THE RAPID ADVANCEMENT OF VYD222 FOR THE PREVENTION OF SYMPTOMATIC COVID-19 IN IMMUNOCOMPROMISED PEOPLE Anticipated development path for VYD222 Early March 2023: Elected VYD222 for clinical advancement, with plans to leverage adintrevimab data to accelerate the development of VYD2
Slide 13: Strong rationale for using surrogates of clinical efficacy in clinical trials
STRONG RATIONALE FOR USING SURROGATES OF CLINICAL EFFICACY IN CLINICAL TRIALS, POTENTIALLY ACCELERATING DEVELOPMENT OF VYD222 AND FUTURE CANDIDATES Serum neutralizing titers (either mAb or vaccine-induced) correlate with protection against symptomatic SARS-CoV-2 infection across multiple variants Va
Slide 14: Evolving regulatory paradigm supports Invivyd's vision and strategy
EVOLVING REGULATORY PARADIGM PROVIDES SUPPORT FOR INVIVYD’S VISION AND STRATEGY THE PAST TODAY VISION FOR THE FUTURE • A single SARS-CoV-2 directed • Multiple SARS-CoV-2 directed • A portfolio of mAbs on the market mAb candidate: adintrevimab mAbs in discovery or development to address SARS-CoV-2 an
Slide 15: VYD222 is one of many antibodies in Invivyd's robust pipeline
VYD222 IS ONE OF MANY ANTIBODIES IN INVIVYD’S ROBUST PIPELINE DEVELOPMENT STATUS PROGRAMS PLATFORM INDICATION(S) STATUS DISCOVERY/ IND-ENABLING PHASE 1 PHASE 2 PHASE 3 PRECLINICAL CORONAVIRUSES Initial Ph 1 data VYD222 mAb Prevention reported in Q2 2023 Engineering Prevention or VYD224 mAb variant m
Slide 16: Invivyd is positioned to potentially fulfill a large unmet need
INVIVYD IS POSITIONED TO POTENTIALLY FULFILL A LARGE UNMET NEED Providing vulnerable populations, such as immunocompromised people, with protection from COVID-19 is a long-term, large opportunity Invivyd is executing on its strategy to rapidly advance VYD222, with the recent announcement of positive
Slide 17: Management team with track record of success
MANAGEMENT TEAM WITH TRACK RECORD OF SUCCESS Peter C. Schmidt, M.D., MSc Stacy Price, M.S. Dave Hering Chief Medical Officer Chief Technology & Chief Executive Officer & Director Manufacturing Officer Jill Andersen, J.D. Jeremy Gowler Robert Allen, Ph.D. Chief Legal Officer & Corporate Secretary Chi
Slide 18: Thank You
Thank You © 2023 Invivyd, Inc. Invivyd and the Invivyd logo are trademarks of Invivyd, Inc. All trademarks in this presentation are the property of their respective owners.